CURRENT INTELLIGENCE BULLETIN 23 ETHYLENE DIBROMIDE AND DISULFIRAM TOXIC INTERACTION TABLE OF CONTENTS
Identifiers and Synonyms for Disulfiram Identifiers and Synonyms for Ethylene Dibromide
J. Donald Millar Correspondence Background---Ethylene Dibromide Background---Disulfiram
Laboratory Animal Study of Toxic Interaction NIOSH Recommendations
IDENTIFIERS AND SYNONYMS FOR DISULFIRAM
Chemical Abstracts Service Registry Number 97-77-8
IDENTIFIERS AND SYNONYMS FOR ETHYLENE DIBROMIDE
Chemical Abstracts Service Registry Number 106-93-4
ETHYLENE DISULFIRAM INTERACTION
The National Institute for Occupational Safety and Health (NIOSH) recommends that no worker be
exposed to both ethylene dibromide and disulfiram (Antabuse®, Ro-Sulfirarm®, tetraethylthiuram disulfide; additional synonyms are tabulated in the appendix). This interim recommendation is based on
preliminary results of NIOSH research currently in progress which suggests a serious toxic interaction between inhaled ethylene dibromide and ingested disulfiram resulting in exceedingly high mortality of laboratory rats.
This Bulletin summarizes the current status of the NIOSH study, other pertinent data, occupational
health implications, and NIOSH recommendations for reducing the risk from the toxic interaction.
Background --- Ethylene Dibromide
Approximately 300 million pounds of ethylene dibromide are produced annually in the United States. Ethylene dibromide, a volatile liquid, is used primarily as a lead scavenger in leaded fuels (to retard lead
deposition in the engine), but this use is decreasing as the consumption of leaded gasoline decreases. Ethylene dibromide is also used as a soil, grain) and fruit fumigant, as an intermediate in the synthesis of
dyes and pharmaceuticals, and as a solvent for resins, gums, and waxes. NIOSH estimates that approximately 9,000 employees are potentially exposed to ethylene dibromide during the course of these uses.1 In addition, an estimated 650,000 gasoline station attendants are potentially exposed to very low levels of ethylene dibromide.1 McDermott and Killiany have estimated maximum expected airborne
concentrations of ethylene dibromide to be 0.08 parts per million parts of air (ppm) at 500 ppm leaded gasoline vapor in air.2
An employee exposure ceiling of 0.13 ppm (1.0 mg/m3), as determined over any fifteen-minute sampling period, was recommended by NIOSH in August 1977 for ethylene dibromide.1 However, toxic interaction effects with other chemicals were not considered in the development of this recommended standard. The current Occupational Safety and Health Administration, Department of Labor, standard
for occupational exposure to ethylene dibromide is 20 ppm (8-hour time-weighted average).
Ethylene dibromide itself is a very toxic compound. Reported adverse health effects of employees chronically exposed to ethylene dibromide may include the induction of cancer and sterility as well as
malformations and heritable changes in offspring. Ethylene dibromide may also cause adverse effects to the liver, kidneys, heart, and other internal organs and systems. Skin contact with ethylene dibromide
may cause chemical burns as well as systemic effects due to absorption of ethylene dibromide through the skin. A summary of the health effects of ethylene dibromide may be found in the NIOSH Criteria Document.1
Background --- Disulfiram
Disulfiram is a prescription drug used as an alcohol deterrent and also is an accelerator used in the manufacture of rubber. Disulfiram may also be used as a fungicide and insecticide.
Disulfiram is widely used in alcoholism control programs under the tradenames Antabuse® and Ro-
Sulfiram®. The intake of even small quantities of ethanol (ethyl alcohol) while on disulfiram results in flushing, breathing difficulty, nausea, vomiting, and low blood pressure. This violent and unpleasant
reaction reinforces an individual's resolve to abstain from alcohol. The human therapeutic dose of disulfiram ranges from 125 to 500 mg/day; disulfiram therapy may continue for many months, even
Although the literature does contain reports of carcinogenic effects of disulfiram in laboratory animals, the International Agency for Research in Cancer (IARC) has concluded that, "the limited data available do not allow an evaluation of the carcinogenicity of disulfiram to be made."3 Disulfiram is currently being tested for carcinogenicity by the National Cancer Institute.
NIOSH estimates that approximately 70,000 workers have occupational exposure to disulfiram. This estimate is based on the NIOSH National Occupational Hazard Survey which was conducted between
1972 and 1974, and included over 500,000 employees at 4,775 facilities. In addition, there may be as many as 100,000 people on disulfiram therapy for alcoholism.
Laboratory Animal Study of Toxic Interaction
In the NIOSH-sponsored research currently in progress, laboratory rats exposed to 20 ppm ethylene
dibromide by inhalation (the current 8-hour TWA OSHA exposure standard) and also receiving a diet containing 0.05% disulfiram are experiencing exceedingly high mortality levels as well as a high
incidence of tumors (including hemangiosarcomas of the liver, spleen, and kidney). Even in those sites where tumors often occur spontaneously in rats, such as the mammary gland in females, the incidence of
tumors appears to be increased and the tumors are occurring at an earlier than expected age. These results are preliminary and control animals have not yet been completely studied. Although the clinical
significance of the data has not yet been evaluated, great caution is indicated.
The NIOSH-sponsored research is being conducted by Midwest Research Institute, Kansas City,
Missouri, under NIOSH contract #210-76-0131 (September 29, 1976 to January 31, 1979). Four groups of animals are in the study, each group comprised of 48 male and 48 female Sprague-Dawley rats. After
approximately thirteen months of exposure, 45 of the 48 male and 47 of the 48 female rats exposed simultaneously to ethylene dibromide and disulfiram have died or have been terminated because they
were dying (due to the formation of tumors.) A description of the four groups as well as a summary of their mortality experience at the end of approximately thirteen months of treatment is presented in Table
TABLE 1 - Number of Deaths or Terminations/Total Number of Treatment MaleFemale
The extent to which this toxic interaction is specific for ethylene dibromide and disulfiram is not known. Similar toxic interactions may occur between disulfiram, as well as chemicals structurally related to
disulfiram, and other halogenated hydrocarbons.
While current NIOSH research continues and its significance is further evaluated, it is recommended, as an interim and prudent measure, that no worker be exposed to both ethylene dibromide and disulfiram.
Workers should not be exposed to ethylene dibromide durining the course of disulfiram therapy.
Disulfiram (Antabuse®, Ro-Sulfiram®) should not be administered to workers having potential occupational exposure to ethylene dibromide except in those cases where, in the best judgment of the
responsible physician, the benefit of disulfiram therapy strongly outweighs the risk to the particular patient.
Whenever disulfiram [bis(diethylthiocarbamoyl) disulfide, tetraethylthiuram disulfide] is used in the
workplace (e.g., as an accelerator in rubber production, as a fungicide or insecticide), precautions should be taken so that no worker is exposed to both ethylene dibromide and disulfiram.
Although NIOSH recognizes the complexity and many combinations possible in evaluating toxic interactions between various agents, NIOSH believes this is an area in need of further attention and
1. Criteria for a Recommended Standard . . . . Occupational Exposure to Ethylene Dibromide, U.S.
Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, Cincinnati, Ohio, August 1977.
2. McDermott, H. J., and Killiany, S. E., Jr., "Quest for a Gasoline TLV," Am. Ind. Hyg. Assoc. J.,
3. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals in Man, 12, 85-95,
Copies of this and other NIOSH documents are available from:
National Institute for Occupational Safety and Health
For further information about occupational safety and health, call
Problems of Forensic Sciences 2010, vol. LXXXIII DETERMINATION OF CITALOPRAM AND ITS ENANTIOMERS BY MEANS OF CHROMATOGRAPHIC TECHNIQUES 1 De part ment of An a lyt i cal Chem is try, Jagiellonian Uni ver sity, Kraków, Po land2 Laboratory of En vi ron men tal Re search, De part ment of Tox i col ogy, Uni ver sity of Med i cal Sciences, Poznañ, Po land Ab stract This pa per pres ents a r
Leicester City Clinical Commissioning Group Governing Body LEICESTER CITY CLINICAL COMMISSIONING GROUP GOVERNING BODY MEETING 12 NOVEMBER 2013 Title of the report: Cephalosporin and Quinolone Prescribing Audit, Re-Audit and Rachel Oldridge, Acting Head of Prescribing Presenter: Purpose of report: The report addresses the Executive Committee’s proposal to fund addition